Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Phase 4

Completed

Conditions: Chronic Renal Anemia

Interventions: Drug: Darbepoetin Alfa
Drug: Epoetin Alfa
Drug: Epoetin Beta
Drug: methoxy polyethylene glycol-epoetin beta

First Posted Date: 2008-10-16

Last Posted Date: 2019-08-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2825

Registration Number: NCT00773513

Locations: 🇦🇺
Gosford Hospital; Renal, Gosford, New South Wales, Australia
🇭🇷
General Hospital Josip Bencevic; Department of Haemodialysis, Slavonski Brod, Croatia
🇦🇺
Renal Research Dr Simon Roger, Gosford, New South Wales, Australia

and more 193 locations

A Monocenter, Open-Label Glucose Clamp Study Examining the Metabolic Effect of Insulin Infusion Intervals for Basal Insulin Infusion in Patients With Type I Diabetes

Not Applicable

Completed

Conditions: Diabetes Mellitus Type 1

Interventions: Device: Accu-Chek Spirit Insulin Pump
Device: Comparator insulin pump

First Posted Date: 2008-10-15

Last Posted Date: 2016-03-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 14

Registration Number: NCT00772356

A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Phase 3

Completed

Conditions: Idiopathic Thrombocytopenic Purpura

Interventions: Drug: rituximab
Drug: Dexamethasone

First Posted Date: 2008-10-10

Last Posted Date: 2014-10-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 103

Registration Number: NCT00770562

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Phase 2

Terminated

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: RG1507
Drug: Placebo
Drug: erlotinib [Tarceva]

First Posted Date: 2008-09-26

Last Posted Date: 2021-01-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 171

Registration Number: NCT00760929

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇨🇦
Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, Canada
🇺🇸
North Shore University Health System, Glenview, Illinois, United States

and more 54 locations

A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).

Phase 1

Completed

Conditions: Peripheral Arterial Disease (PAD)

Interventions: Drug: RO4905417
Drug: placebo

First Posted Date: 2008-09-26

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 72

Registration Number: NCT00760565

A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients.

Phase 4

Completed

Conditions: Kidney Transplantation

Interventions: Drug: mycophenolate mofetil
Drug: tacrolimus, low dose
Drug: tacrolimus, standard dose
Drug: corticosteroids

First Posted Date: 2008-09-25

Last Posted Date: 2014-08-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 210

Registration Number: NCT00758602

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Phase 3

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: metformin
Drug: insulin glargine
Drug: taspoglutide

First Posted Date: 2008-09-18

Last Posted Date: 2016-07-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1072

Registration Number: NCT00755287

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

Phase 3

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: Metformin
Drug: Placebo (matching sitagliptin)
Drug: Placebo (matching taspoglutide)
Drug: Sitagliptin
Drug: Taspoglutide

First Posted Date: 2008-09-18

Last Posted Date: 2016-11-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 666

Registration Number: NCT00754988

A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: tocilizumab [RoActemra/Actemra]
Drug: methotrexate

First Posted Date: 2008-09-18

Last Posted Date: 2015-05-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 418

Registration Number: NCT00754572

A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2008-09-18

Last Posted Date: 2016-02-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 286

Registration Number: NCT00754559

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy